Nano-X Imaging Ltd. (NASDAQ:NNOX) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET

Company Participants

Mike Cavanaugh - ICR Westwicke, Investor Relations

Erez Meltzer - Chief Executive Officer and Director

Ran Daniel - Chief Financial Officer

Conference Call Participants

Jeffrey Cohen - Ladenburg

Suraj Kalia - Oppenheimer

Rahul Rakhit - LifeSci Capital

Operator

Ladies and gentlemen, thank you joining us today. And welcome to the Nanox’s Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is may be recorded.

I would now like to hand the conference over to your speaker host, Mike Cavanaugh of Investor Relations. Please go ahead.

Mike Cavanaugh

Good morning, and thank you for joining us today. Earlier today, Nano-X Imaging Limited released its financial results for the quarter ended September 30, 2022. The release is currently available on the Investors section of the company's website. Erez Meltzer, Chief Executive Officer; and Ran Daniel, Chief Financial Officer, will host this morning's call.

Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the company's financial results, research and development, manufacturing and commercialization activities, regulatory process operations and other matters. These statements are subject to risks, uncertainties and assumptions that are based on management's current expectations as of today and may not be updated in the future. Therefore, these statements should not be relied upon as representing the company's views as of any subsequent date.

Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. We will also refer to certain non-GAAP financial measures to provide additional information to investors. A reconciliation of the non-GAAP to GAAP measures is provided with our press release, with the primary differences being amortization of intangible assets, shared-based compensation, secondary offering expenses, goodwill impairment, change in obligation in connection of acquisitions and legal fees and connection with class action litigation and SEC inquiry.

I'd now like to turn the call over to Erez Meltzer.

Erez Meltzer

Thank you, Mike. And thank you all for joining the call today. Reporting on our third quarter of 2022, I'm proud of the results our team has been able to deliver as we continue to advance our commercialization of the Nanox.ARC system. As in our last call, I will give an overview of our recent achievements. And we'll share our outlook for the rest of 2022. Before turning the call over to Ran Daniel, our CFO to review our financial results in detail. We will then open the call up to questions. I'm pleased with the progress our team made during the quarter, which as most of you know includes our 510 (k) submission to the FDA for our multi-source Nanox.ARC system at the end of September, and which is now under FDA review. I'm very proud of the hard work behind the scenes by our regulatory product and other teams to absorb the continuous feedback from our Q submission process and incorporate it into the research submission. We do not have any insights into the timing of the FDA is the response.